BioCentury | Nov 7, 2020
Regulation

Aducanumab panel criticizes FDA as it rebukes Alzheimer’s candidate

...have problem characterizing it as overwhelmingly positive,” added Madhav Thambisetty, senior investigator and chief of the National Institute on Aging’s...
BioCentury | Sep 19, 2020
Translation in Brief

Gene therapies from Passage Bio, Locanabio; Lava’s antitumor bispecific, health disparities in Alzheimer’s and more

...raise fresh venture funding (see “Lava’s $83M Series C”).NIH biomarker study in Mexican Americans with Alzheimer’sNIH’s National Institute on Aging...
BioCentury | Aug 21, 2020
Deals

Aug. 20 Quick Takes: Funding for Alzheon’s Alzheimer’s Phase III; plus Merck, FDA guidance, LumiraDx, RACE for Children, blood plasma and Novo-Evotec

...By BioCentury Staff Alzheon preps trial with $47M grantNIH’s National Institute on Aging (NIA) will provide $47 million to...
BioCentury | Jun 27, 2020
Translation in Brief

Regeneron enhances checkpoint therapy with CD28 bispecifics; plus NIH funds Alzheimer’s brain mapping, Genentech and more

...costimulatory bispecifics paired with anti-CD3 bispecifics” ). NIH funds brain mapping center with $41M NIH’s National Institute on Aging...
...of transcription 3 TEAD - TEA domain family member BioCentury Staff Regeneron Pharmaceuticals Inc. Genentech Inc. Roche Dana-Farber Cancer Institute Allen Institute National Institute on Aging Broad...
BioCentury | Jan 10, 2020
Product Development

Seeking structural endpoints for OA

As the first disease-modifying therapies for osteoarthritis enter late-stage development, companies are testing new endpoints that can capture effects on joint structure instead of relying on traditional pain-related readouts. Most are converging on MRI imaging...
BioCentury | Oct 2, 2019
Preclinical News

New NIH centers to validate Alzheimer’s targets

...with the formation of two new research centers tasked with validating new drug targets. NIH’s National Institute on Aging...
...along the way. “Everything coming out of the centers will be open source.” Lorenzo Refolo, National Institute on Aging...
...Did We Get Here and What Can We Learn” ). Lauren Martz, Associate Editor National Institutes of Health National Institute on Aging...
BioCentury | Mar 23, 2019
Product Development

Baby steps beyond beta amyloid

...chart shows targeting strategies alternative to β amyloid and tau grouped by BioCentury using the National Institute on Aging...
BioCentury | Feb 15, 2019
Product R&D

A bug about Alzheimer’s

...be done before spending any more money on this mechanism,” he said. Last year, NIH’s National Institute on Aging...
...School, Boston, Mass. Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Massachusetts General Hospital, Boston, Mass. National Institute on Aging...
BioCentury | Dec 7, 2018
Tools & Techniques

Filaments line up as MS biomarker

...symptoms aren’t yet present, although it did not name a specific biomarker. In April, NIH’s National Institute on Aging...
...San Francisco, Calif. Iron Horse Diagnostics Inc., Scottsdale, Ariz. Meso Scale Diagnostics LLC, Rockville, Md. National Institute on Aging...
BioCentury | Oct 11, 2018
Translation in Brief

Public funding highlights: 3Q18

...up to $35 million through National Center for Complementary and Integrative Health (NCCIH) and the National Institute on Aging...
Items per page:
1 - 10 of 70
BioCentury | Nov 7, 2020
Regulation

Aducanumab panel criticizes FDA as it rebukes Alzheimer’s candidate

...have problem characterizing it as overwhelmingly positive,” added Madhav Thambisetty, senior investigator and chief of the National Institute on Aging’s...
BioCentury | Sep 19, 2020
Translation in Brief

Gene therapies from Passage Bio, Locanabio; Lava’s antitumor bispecific, health disparities in Alzheimer’s and more

...raise fresh venture funding (see “Lava’s $83M Series C”).NIH biomarker study in Mexican Americans with Alzheimer’sNIH’s National Institute on Aging...
BioCentury | Aug 21, 2020
Deals

Aug. 20 Quick Takes: Funding for Alzheon’s Alzheimer’s Phase III; plus Merck, FDA guidance, LumiraDx, RACE for Children, blood plasma and Novo-Evotec

...By BioCentury Staff Alzheon preps trial with $47M grantNIH’s National Institute on Aging (NIA) will provide $47 million to...
BioCentury | Jun 27, 2020
Translation in Brief

Regeneron enhances checkpoint therapy with CD28 bispecifics; plus NIH funds Alzheimer’s brain mapping, Genentech and more

...costimulatory bispecifics paired with anti-CD3 bispecifics” ). NIH funds brain mapping center with $41M NIH’s National Institute on Aging...
...of transcription 3 TEAD - TEA domain family member BioCentury Staff Regeneron Pharmaceuticals Inc. Genentech Inc. Roche Dana-Farber Cancer Institute Allen Institute National Institute on Aging Broad...
BioCentury | Jan 10, 2020
Product Development

Seeking structural endpoints for OA

As the first disease-modifying therapies for osteoarthritis enter late-stage development, companies are testing new endpoints that can capture effects on joint structure instead of relying on traditional pain-related readouts. Most are converging on MRI imaging...
BioCentury | Oct 2, 2019
Preclinical News

New NIH centers to validate Alzheimer’s targets

...with the formation of two new research centers tasked with validating new drug targets. NIH’s National Institute on Aging...
...along the way. “Everything coming out of the centers will be open source.” Lorenzo Refolo, National Institute on Aging...
...Did We Get Here and What Can We Learn” ). Lauren Martz, Associate Editor National Institutes of Health National Institute on Aging...
BioCentury | Mar 23, 2019
Product Development

Baby steps beyond beta amyloid

...chart shows targeting strategies alternative to β amyloid and tau grouped by BioCentury using the National Institute on Aging...
BioCentury | Feb 15, 2019
Product R&D

A bug about Alzheimer’s

...be done before spending any more money on this mechanism,” he said. Last year, NIH’s National Institute on Aging...
...School, Boston, Mass. Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Massachusetts General Hospital, Boston, Mass. National Institute on Aging...
BioCentury | Dec 7, 2018
Tools & Techniques

Filaments line up as MS biomarker

...symptoms aren’t yet present, although it did not name a specific biomarker. In April, NIH’s National Institute on Aging...
...San Francisco, Calif. Iron Horse Diagnostics Inc., Scottsdale, Ariz. Meso Scale Diagnostics LLC, Rockville, Md. National Institute on Aging...
BioCentury | Oct 11, 2018
Translation in Brief

Public funding highlights: 3Q18

...up to $35 million through National Center for Complementary and Integrative Health (NCCIH) and the National Institute on Aging...
Items per page:
1 - 10 of 70